Literature DB >> 26287684

Identification of a Human Natural Killer Cell Lineage-Restricted Progenitor in Fetal and Adult Tissues.

Virginie M Renoux1, Alya Zriwil2, Claudia Peitzsch1, Jakob Michaëlsson3, Danielle Friberg4, Shamit Soneji2, Ewa Sitnicka5.   

Abstract

Natural killer (NK) cells are cytotoxic lymphocytes and play a vital role in controlling viral infections and cancer. In contrast to B and T lymphopoiesis where cellular and regulatory pathways have been extensively characterized, the cellular stages of early human NK cell commitment remain poorly understood. Here we demonstrate that a Lin(-)CD34(+)CD38(+)CD123(-)CD45RA(+)CD7(+)CD10(+)CD127(-) population represents a NK lineage-restricted progenitor (NKP) in fetal development, umbilical cord blood, and adult tissues. The newly identified NKP has robust NK cell potential both in vitro and in vivo, generates functionally cytotoxic NK cells, and lacks the ability to produce T cells, B cells, myeloid cells, and innate lymphoid-like cells (ILCs). Our findings identify an early step to human NK cell commitment and provide new insights into the human hematopoietic hierarchy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26287684     DOI: 10.1016/j.immuni.2015.07.011

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  65 in total

Review 1.  Tissue-Resident Cytolytic Innate Lymphocytes in Cancer.

Authors:  Briana G Nixon; Ming O Li
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  Cellular pathways in the development of human and murine innate lymphoid cells.

Authors:  Steven D Scoville; Aharon G Freud; Michael A Caligiuri
Journal:  Curr Opin Immunol       Date:  2018-12-19       Impact factor: 7.486

3.  CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway.

Authors:  Luxi Chen; Youssef Youssef; Cameron Robinson; Gabrielle F Ernst; Mary Y Carson; Karen A Young; Steven D Scoville; Xiaoli Zhang; Regine Harris; Palak Sekhri; Anthony G Mansour; Wing K Chan; Ansel P Nalin; Hsiaoyin C Mao; Tiffany Hughes; Emily M Mace; Yinghong Pan; Navin Rustagi; Sujash S Chatterjee; Preethi H Gunaratne; Gregory K Behbehani; Bethany L Mundy-Bosse; Michael A Caligiuri; Aharon G Freud
Journal:  Immunity       Date:  2018-09-04       Impact factor: 31.745

Review 4.  Emerging insights into natural killer cells in human peripheral tissues.

Authors:  Niklas K Björkström; Hans-Gustaf Ljunggren; Jakob Michaëlsson
Journal:  Nat Rev Immunol       Date:  2016-04-28       Impact factor: 53.106

Review 5.  NK cells and type 1 innate lymphoid cells: partners in host defense.

Authors:  Hergen Spits; Jochem H Bernink; Lewis Lanier
Journal:  Nat Immunol       Date:  2016-06-21       Impact factor: 25.606

Review 6.  Dissecting human ILC heterogeneity: more than just three subsets.

Authors:  Yannick Simoni; Evan W Newell
Journal:  Immunology       Date:  2017-12-26       Impact factor: 7.397

Review 7.  ILC3 in Axial Spondyloarthritis: the Gut Angle.

Authors:  Daniele Mauro; Federica Macaluso; Serena Fasano; Riccardo Alessandro; Francesco Ciccia
Journal:  Curr Rheumatol Rep       Date:  2019-06-13       Impact factor: 4.592

Review 8.  The Expanding Role of Natural Killer Cells in Type 1 Diabetes and Immunotherapy.

Authors:  Chris Fraker; Allison L Bayer
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

9.  Human innate lymphoid cell precursors express CD48 that modulates ILC differentiation through 2B4 signaling.

Authors:  Dejene M Tufa; Ashley M Yingst; George Devon Trahan; Tyler Shank; Dallas Jones; Seonhui Shim; Jessica Lake; Kevin Winkler; Laura Cobb; Renee Woods; Kenneth Jones; Michael R Verneris
Journal:  Sci Immunol       Date:  2020-11-20

Review 10.  The Broad Spectrum of Human Natural Killer Cell Diversity.

Authors:  Aharon G Freud; Bethany L Mundy-Bosse; Jianhua Yu; Michael A Caligiuri
Journal:  Immunity       Date:  2017-11-21       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.